3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid has been researched along with Pain in 9 studies
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Agmatine, an endogenous cationic amine resulting from the decarboxylation of L-arginine, produces antihyperalgesic and antiallodynic effects in animal models of chronic neuropathic and inflammatory pain." | 3.74 | Agmatine induces antihyperalgesic effects in diabetic rats and a superadditive interaction with R(-)-3-(2-carboxypiperazine-4-yl)-propyl-1-phosphonic acid, a N-methyl-D-aspartate-receptor antagonist. ( Courteix, C; Eschalier, A; Fialip, J; Hernandez, A; Pélissier, T; Privat, AM, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morales, F | 1 |
| Constandil, L | 1 |
| Pelissier, T | 2 |
| Hernández, A | 2 |
| Laurido, C | 1 |
| Courteix, C | 1 |
| Privat, AM | 1 |
| Eschalier, A | 1 |
| Fialip, J | 1 |
| Larson, AA | 2 |
| Sun, X | 1 |
| Goettl, VM | 1 |
| Øye, I | 1 |
| Mathisen, LC | 1 |
| Pollard, M | 1 |
| Kristensen, JD | 1 |
| Svensson, B | 1 |
| Gordh, T | 1 |
| Woolf, CJ | 1 |
| Thompson, SWN | 1 |
| Eaton, SA | 1 |
| Salt, TE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Racemic Ketamine on Pain in Females and Males After Surgical Removal of Third Molars[NCT00232492] | Phase 4 | 128 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Intra-operative Magnesium Sulphate for Post-operative Pain in Patients Undergoing Total Abdominal Hysterectomy Under General Anesthesia[NCT06026527] | Phase 3 | 42 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| A Prospective, Randomized, Single Blinded Comparison of Intraoperative Ketamine Infusion Versus Placebo in Patients Having Spinal Fusion[NCT02424591] | Phase 4 | 46 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Beck's Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures attitudes and symptoms of depression. Each sentence has a rating from 0 to 3 and the sentences go from mild to fairly severe descriptions of moods. The numbers are tabulated, the lowest possible score is 0 and the highest is 63.~A score of 1-10 indicates normal ups and downs. 11-16 indicates a mild mood disturbance; 17-20, borderline clinical depression; 21-30, moderate depression; 31-40, severe depression; over 40, extreme depression" (NCT02424591)
Timeframe: Post-op Day 3
| Intervention | points (Median) |
|---|---|
| Ketamine | 8 |
| Placebo | 9 |
"McGill Short Form measures pain in different ways. The first part of the form lists 15 adjectives for pain, for which the answers can be none (0), Mild (1), Moderate (2) and Severe (3). Descriptors 1-11 represent the sensory dimension of pain experience and 12-15 represent the affective dimension. A score of 0 is good, and a score of 45 indicates extreme pain. The lower the score the less pain a subject feels (better), as the scores go up, so do the pain levels (worse).~PPI (Present Pain Intensity) asks patients to measure pain from 0 (no pain) to 5 (excruciating). Again, a lower score is ideal." (NCT02424591)
Timeframe: Post-op Day 3
| Intervention | points (Median) |
|---|---|
| Ketamine | 11 |
| Placebo | 10.5 |
Quality of Recovery 15 questions questionnaires that ask, on a scale of 0-10, with 0 always being bad and 10 always being best, how the patient is recovering. The total number is reviewed, so the highest total score possible is 150 and the lowest is 0. (NCT02424591)
Timeframe: Post-op Day 3
| Intervention | points (Median) |
|---|---|
| Ketamine | 95 |
| Placebo | 101 |
9 other studies available for 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Pain
| Article | Year |
|---|---|
Antinociceptive interaction of (±)-CPP and propentofylline in monoarthritic rats.
Topics: Animals; Arthritis, Experimental; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Co | 2012 |
Agmatine induces antihyperalgesic effects in diabetic rats and a superadditive interaction with R(-)-3-(2-carboxypiperazine-4-yl)-propyl-1-phosphonic acid, a N-methyl-D-aspartate-receptor antagonist.
Topics: Agmatine; Animals; Anticonvulsants; Diabetes Mellitus, Experimental; Drug Interactions; Excitatory A | 2007 |
The amino-terminus of substance P mimics and MK-801 attenuates the effects of capsaicin on nociception and kainic acid-induced behavior in the mouse.
Topics: Analysis of Variance; Animals; Capsaicin; Dizocilpine Maleate; Haloperidol; Kainic Acid; Male; Mice; | 1993 |
Antinociception induced by 3-((+-)-2-carboxypiperazin-4-yl)-propyl-1- phosphonic acid (CPP), an N-methyl-D-aspartate (NMDA) competitive antagonist, plus 6,7-dinitroquinoxaline-2,3-dione (DNQX), a non-NMDA antagonist, differs from that induced by MK-801 pl
Topics: Animals; Dizocilpine Maleate; Formaldehyde; Injections, Spinal; Male; Mice; Pain; Pain Measurement; | 1994 |
The effect of CPP in neurogenic pain: inhibition of spinal or cortical NMDA receptors?
Topics: Cerebral Cortex; Humans; Pain; Piperazines; Receptors, N-Methyl-D-Aspartate; Spinal Cord | 1993 |
Ionotropic glutamate receptor-mediated responses in the rat primary somatosensory cortex evoked by noxious and innocuous cutaneous stimulation in vivo.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Excitatory Amino Acid Antagonists | 2000 |
The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans.
Topics: Cold Temperature; Female; Hot Temperature; Humans; Injections, Spinal; Lidocaine; Middle Aged; Pain; | 1992 |
The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states.
Topics: Action Potentials; Animals; Dizocilpine Maleate; Motor Neurons; Mustard Plant; Pain; Physical Stimul | 1991 |
The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states.
Topics: Action Potentials; Animals; Dizocilpine Maleate; Motor Neurons; Mustard Plant; Pain; Physical Stimul | 1991 |
The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states.
Topics: Action Potentials; Animals; Dizocilpine Maleate; Motor Neurons; Mustard Plant; Pain; Physical Stimul | 1991 |
The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states.
Topics: Action Potentials; Animals; Dizocilpine Maleate; Motor Neurons; Mustard Plant; Pain; Physical Stimul | 1991 |
Thalamic NMDA receptors and nociceptive sensory synaptic transmission.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Hot Temperature; Male; Nociceptors | 1990 |